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Objective:  To assess the prevalence of psychotic symptoms among youths (age 14-25 years) with a 
childhood diagnosis of attention-deficit/hyperactivity disorder (ADHD) combined type.   Method: The 
participants in the Multimodal Treatment Study of Children with ADHD (MTA) and a local normative 
comparison group (LNCG) were systematically assessed 6, 8, 10, 12, 14, and 16 years after the original 
enrollment at a mean age of 8.5 years.  Trained research assistants administered a psychosis screener, 
and positive screens were referred to study clinicians to confirm or exclude psychosis.  Possible 
associations between screening positive and alcohol or substance use were assessed.   Results: Data 
were available from 509 MTA participants (88% of the original MTA sample) and 276 LNCG subjects 
(96% of the original sample), with a mean age of 25.1 and 24.6 years, respectively, at Year 16.   Twenty-
six MTA subjects (5%, 95% CI: 3, 7) and 11 LNCG (4%, 95% CI: 2, 6) screened positive for at least one 
psychotic symptom (p=0.60).  Most psychotic symptoms were transient.  The prevalence of clinician-
confirmed psychotic symptoms was 1.1% (95% C.I. 0.2, 2.1) in the MTA and 0.7% (0, 1.7) in the LNCG 
(p=0.72).  Greater cannabis use was reported by those who screened (p<0.05) and were confirmed 
positive (p<0.01).  Conclusions: There was no evidence that ADHD increased the risk for psychotic 
symptoms.  In both the ADHD and normative comparison groups, more frequent cannabis use was 
associated with greater likelihood of experiencing psychotic symptoms, thus supporting the 





Introduction   
 
Attention deficit/hyperactivity disorder (ADHD) is a common disorder of childhood that tends to 
persist into adolescence and adulthood.  Psychotic disorders are rare before puberty, but their incidence 
increases in adolescence and peaks in early adult life.  Schizophrenia, which has a population life-time 
morbidity risk of 0.7%, has onset in the second or third decade of life, and early onset schizophrenia, 
defined as onset before 18 years of age, accounts for about one-fourth of the cases.1 Schizophrenia is 
typically preceded by functional impairments and developmental delays,2 and ADHD symptoms are 
often part of the prodrome of psychosis.3-4 
While the prevalence of psychotic disorders is low, isolated psychotic experiences are relatively 
common during development.   A 3.7% prevalence of hallucinations and/or delusions was recently 
reported in a community sample of 7,054 youths aged 11-21 years.5 A 7% prevalence of psychotic 
experiences was found in an epidemiological sample of 1,112 adolescents aged 13-16 years.6 Sub-
threshold symptoms, such as unusual thoughts and auditory misperceptions (illusions), are even more 
common, with rates as high as 12% in youth.5  
Psychotic symptoms are diagnostically non-specific and can be found in the context of 
conditions other than schizophrenia, such as major depression, mania, substance abuse, seizure 
disorders, and other neurological disturbances.7 Population-based epidemiological surveys indicate that 
the mean life-time prevalence of psychotic experiences in non-clinically referred general population is 





The association between ADHD symptoms and psychosis has been mainly studied by 
retrospective assessments of adults diagnosed with a psychotic disorder.  A study of 122 adult patients 
with first-episode schizophrenia-spectrum disorders reported an ADHD prevalence of 17%.11 Few data 
are available on the rate of psychosis in ADHD samples.  A 10-year prospective case-control study of 140 
children with ADHD and 120 matched controls did not find a difference in the rate of psychosis.12   One 
case of psychotic disorder was found in a systematic follow-up of 135 men, mean age of 41 years, who 
were diagnosed with ADHD in childhood.13 However, another study, which followed 208 children with 
ADHD up to a mean age of 31.1 years, found a 3.8% incidence of schizophrenia, representing a 
significant increase over the general population rate of 0.7%.14  An increased risk for schizophrenia and 
bipolar among relatives of people with ADHD was also reported.15 
We report here on the results of a 10-year prospective screening for psychotic symptoms 
conducted on a large cohort of individuals first diagnosed as children with ADHD combined type and a 
normative comparison group.16.17 As part of the systematic follow-up assessments of the participants in 
the Multimodal Treatment Study of Children with ADHD (MTA), a screener for possible psychotic 
symptoms was periodically administered over a 10-year period (year 6 to year 6 after baseline) up to a 
mean age of 25 years.   In parallel, a local normative comparison group (LNCG) received the same 
assessments.  These data were analyzed to examine whether psychotic symptoms occurred more 
frequently in the MTA sample compared to the LNCG.  In addition, possible associations of positive 
psychosis screening with substance abuse, IQ and parental mental illness, which had previously been 








Design   
This was a systematic follow-up of the subjects who participated in the Multimodal Treatment 
Study of Children with ADHD (MTA), whose design and results have been extensively reported.16, 20  At 
the end of the 14-month clinical trial, participants were naturalistically treated in the community and 
eligible for periodic follow-up assessments to evaluate mental health and other domains of functioning.  
Sample 
The MTA sample has been described in detail in previous publications.16  Briefly, it consisted of 
579 children, between 7.0 and 9.9 years of age (mean+SD: 8.5+0.8 years), 80% male, 61% white, 20% 
African American, and 8% Hispanic, meeting DSM-IV criteria for ADHD-combined type, who were 
randomized to receive pharmacotherapy with stimulant medication, behavior therapy, their 
combination, or community care, for 14 months, and afterwards were treated naturalistically and 
periodically reassessed for the following 15 years.17,21,22  Among the exclusion criteria for MTA 
participation (as assessed at age 7-9 years), were: IQ below 80, DSM-IV diagnosis of bipolar disorder, 
psychosis, impairing OCD, or Tourette’s syndrome, use of neuroleptic medication in previous 6 months, 
suicidal or homicidal behavior, and major neurological or medical illness.   A local normative comparison 
group (LNCG) was added to the follow-up study, consisting of 289 subjects randomly selected from the 
same schools and grades, with the same sex proportion as the MTA patients and with the same 
inclusion/exclusion criteria except for ADHD diagnosis.   At baseline, the LNCG received a comprehensive 
assessment battery, which included also the Diagnostic Interview Schedule for Children-Version IV and 
teacher-reported ratings of ADHD.22 LNCG children were not excluded for having symptoms of ADHD.  
However, sensitivity analyses were conducted after excluding 27 LNCG children who met diagnostic 





Psychotic symptoms were assessed at six time points:  6, 8, 10, 12, 14, and 16 years after the 
original MTA study entry.  At each assessment point, trained research assistants interviewed and rated 
the subjects for possible psychotic symptoms using the Psychosis Screener and Follow-Up Diagnostic 
Impression (see Supplemental Appendix).  Raters were not blind to subject status (i.e., MTA or LNCG).  
Subjects were asked about having experienced perceptions suggestive of auditory, visual, or 
somatic/tactile hallucinations, and assessed for possible unusual ideas or thoughts suggestive of 
delusional thinking.   The screening for somatic/tactile hallucinations started with the Year 12 
assessment.  As part of the interview, subjects were assessed for disorganized speech and unusual or 
bizarre behavior, and for possible negative symptoms of psychosis, including flat affect, social 
withdrawal, and poverty of thoughts.  The raters were trained to be broadly inclusive.  Experiences and 
signs that could not be explained otherwise were considered possibly psychotic.  
Positive psychotic symptoms (i.e., auditory, visual, and somatic/tactile hallucinations and 
delusions) were each scored by the rater as 1 (absent), 2 (possibly present but not psychotic), 3 
(probably present and psychotic), or 4 (definitively present and psychotic).  Negative psychotic 
symptoms (i.e., disorganized speech or appearance, inappropriate and flat affect, and social withdrawal) 
were rated as 1 (absent), 2 (mild, e.g., minimal emotional expression), 3 (moderate, e.g., monotone 
speech, poor eye contact), or 4 (severe, e.g., no emotional expression, no connection with interviewer).   
Subjects with a screening rating score of 3 or above on any of the positive symptoms, or of 4 on any of 
the negative symptoms were considered positive at the screening, and referred to the study clinician (a 
child psychiatrist or psychologist).  Following review by the clinician, as spurious and not pathological, 




The Substance Use Questionnaire (SUQ)22,23 was administered at all assessments, beginning with 
the 2-year follow-up.   It asked the subjects about frequency of use of alcohol and other substances 
(e.g., marijuana, inhalants) within the past 6 months (at the 2 to 10 year follow-up) and within the past 
12 months (at the 12 to 16 year follow-up).  Responses were recoded to estimated number of times 
alcohol, marijuana, or another substance, respectively, was used in 12 months, and, for each subject, 
the average times of use across all the assessment points was computed and used for the analyses. For 
nicotine, the subjects were asked to indicate use of cigarettes or other forms of tobacco in the past 
month at the 2 to 10 year follow-up assessments, and in the past 12 months at the 12 to 16 year follow-
up assessments.  For each assessment point, use was scored as 0 (did not use at all), 1 (used less than 
daily) and  2 (used daily), and for each subject, the average score across all assessments was computed 
and analyzed. 
In parallel, starting with Year 12, participants self-reported health issues in the previous 2 years, 
including having received a psychiatric diagnosis, such as schizophrenia, schizoaffective disorder, major 
depression, and bipolar disorder.  
The data were collected between 2002 and 2012 at the following clinical sites: University of 
California, Berkley/University of California; Duke University Medical Center; University of California, 
Irvine; Long Island Jewish Medical Center and New York University; McGill University/Montreal 
Children’s Hospital; University of Pittsburgh; and Columbia University/New York State Psychiatric 
Institute and Mount Sinai Medical Center, New York. 
Data analyses 
Standard descriptive statistics were applied to the data.  Group differences were tested with 




significance accepted at two-tail p<0.05 without correction for multiple tests in these secondary 
analyses.    
 
Results 
Psychotic Symptom Screening in ADHD Subjects vs. Normative Group 
Data were available from 509 MTA participants (87.5% of the originally enrolled MTA sample) 
and 276 LNCG subjects (95.5% of the original sample).  The subjects who were retained were compared 
to those lost to follow-up.  In the MTA, the non-retained group (n=70) had a statistically significant 
higher proportion of males, lower IQ, and lower family income than the retained group, but there were 
no differences in race or history of parental mental illness.  In the LNCG, the non-retained group (n=13) 
had lower family income than the retained group, but di not differ with respect to sex, race, IQ, or 
history of parental mental illness.    Among the retained subjects, the MTA differed from the LNCG by 
younger age, lower IQ, and history of parental mental illness (Table 1).   
The number of subjects at each assessment point ranged from 290 to 436 in the MTA group, and 
from 191 to 252 in the LNCG (Table S1).  The mean number of follow-up assessments per subject during 
the 10-year period was 4.7 + SD 1.5 (median= 5) in the MTA and 5.2 + 1.2 (median=6) in the LNCG 
(t=4.79, df=786, p<0.0001).   During the 10-year period of observation, 26 MTA subjects (5%, 95% C.I. 3, 
7) and 11 LNCG (4%, 95% C.I. 2, 6) screened positive for at least one psychotic symptom (Fisher’s exact 
test, p=0.6; Table 2).   
The rates of positive screens did not significantly differ between MTA and LNCG when the 
subgroups with the same number of visits were compared.  Among subjects who had at least 4 




(Fisher’s exact test, p=0.59).  The results of no statistically significant difference between MTA and LNCG 
did not change when sensitivity analyses were conducted excluding the n=27 LNCG with diagnosable 
ADHD (4.0%, 95% C.I. 1.5-6.4) (Supplemental Table 3). 
Of the 26 MTA participants who screened positive, 8 had originally been randomized to 
combined treatment, 7 to medication management only, 4 to behavior therapy, and 7 to community 
comparison.  The difference in the rate of positive screening by the original treatment group was not 
statistically significant. 
Of the 37 subjects who screened positive, 36 had more than one biennial assessment.  Among 
these 36, a positive screen occurred in more than one assessment for 8 subjects (21.6% of the cases), 
while the remaining 29 (78.4% of cases) screened positive only once.   
Delusions, alone or accompanied by another psychotic symptom, accounted for positive 
screening for 55.6% (N=20) of the positive screens.  Auditory hallucinations, alone or with other 
symptoms, accounted for 45.9% (N=17) of the positive screens (Supplemental Table 2).  Negative 
symptoms of psychosis (social isolation and withdrawal) accounted for only one positive screening.  
Screening positive was not associated with sex, ethnicity (Caucasian vs. other), or lower IQ.  
Positive-screened subjects were more likely to have a mother with history of mental health problems 
than the negative screens (Table 3).  
The 37 subjects who screened positive were referred to the study clinician for further 
evaluation.  However, this evaluation was missing for 7 subjects (4 MTA and 3 LNCG).  Among the 26 
MTA positive screens, psychosis was confirmed in 6 cases and ruled out in 16, while 4 had missing 
clinical evaluation.  Among the 11 LNCG positive screens, psychosis was confirmed in 2 cases and 




considering the missing cases “not confirmed”) did not differ significantly between the MTA (1.1%, 95% 
CI: 0.2, 2.1) and LNCG (0.7%, 95% CI: 0.3-1.7) (Fisher exact test: 0.5, NS).  If the cases with missing 
evaluation are considered as “psychosis not excluded”, the rate of psychosis confirmed or not excluded 
was 1.9% (95% CI: 0.6, 2.9) in the MTA and 1.8% (95% CI: 0.2, 3.4) in the LNCG (Fisher exact test: 1.0, NS) 
(Table 2).   
The original MTA treatment assignment of the 9 subjects with confirmed or not excluded 
psychosis was: combined treatment for 3 cases, medication management for 2, and community control 
for the remaining 4 subjects.  
Upon administration of the health survey at assessment Years 12, 14, and 16, a community 
diagnosis of schizophrenia or schizoaffective disorder was reported by 3 of the MTA subjects (0.4%, 95% 
CI: 0.2, 0.95) and 2 of the LNCG subjects (0.7%, 95% CI: 0.3, 1.7).   These 5 subjects were also positive at 
the psychosis screening (2 had clinician’s review and were confirmed psychotic, while the other 3 had 
missing clinician review).  No diagnosis of schizophrenia or schizoaffective disorder was reported by the 
subjects who were negative at the psychosis screening.  
 
 
Psychotic Symptoms and Substances of Abuse  
 Screening positive for psychotic symptoms was associated with greater use of cannabis, but not 
of alcohol, nicotine,  or other substances, in both the MTA and LNCG (Table 4 and Figure 1).  Subjects 
whose psychotic symptoms were confirmed positive reported statistically significant greater use of 
cannabis and nicotine, but not of alcohol or other drugs, than the rest of the sample (Table 5).  These 
results did not change when these analyses were repeated after excluding the n=27 LCNG subjects who 




5).   Nicotine and cannabis use were statistically significantly correlated in both the MTA (Spearman 
correlation coefficient rho=0.47, p<0.0001) and the LCNG (rho=0.59, p<0.0001) groups.  
 
Discussion    
This was a prospective study of youths diagnosed with ADHD combined type in childhood and 
periodically re-assessed up to a mean age of about 25 years.  During a 10-year follow-up period (6 to 16 
years after baseline), 5.1% percent of the ADHD subjects screened positive at least once for a self-
reported psychotic experience.   This rate was not statistically different from that found in a 
concurrently assessed local normative community sample, and is consistent with that reported in 
community samples of youths and adults.5,19  These data indicate that a diagnosis of ADHD does not 
increase the risk of psychotic experiences or of psychotic disorder, a finding that is consistent with other 
follow-up studies of ADHD children into adulthood.13, 24 
The major strength of this study is the consistent and repeated prospective assessments of 
psychosis for a large and well-defined cohort of children with ADHD-combined for 10 years, between 15 
and 25 years of age, a period which is known to be the time of highest risk for developing psychotic 
disorders.  The MTA sample was well characterized at entry, with exclusion of intellectual disability, 
autism, or other major psychopathology. Other strengths are the good sample retention (greater than 
85%) over the years, and the concurrent assessment of a local normative comparison group. 
Several important limitations must be considered.  First, a diagnosis of bipolar or psychotic 
disorder or treatment with neuroleptic medication in the previous 6 months was reason for exclusion 
from the MTA at study screening when participants were 7 to 9 years of age.  While none of the children 
who underwent formal screening for possible participation was excluded because meeting any of these 




not have referred children with psychosis.  However, the LCNG was selected using the same criteria, 
thus attenuating the impact of possible biases.  Second, the screening instrument used for this study 
antedates the development of detailed and probably more sensitive and specific instruments, such as 
the Structured Interview for Prodromal Syndromes, Comprehensive Assessment of At-Risk Mental 
States, or Prodromal Questionnaire, which are now used to assess psychosis in youth.25,26  Third, 
although they were trained to collect data without bias, the raters who interviewed the MTA and LNCG 
subjects were not blind to their group status.  Fourth, data for some clinical reviews following positive 
screening were missing from the database.  As a way of addressing this deficiency, separate analyses 
considering these cases either non-confirmed or not excluded were conducted, without significant 
changes in the results.  Finally, possible family history of psychosis was not part of the database.   In 
support of the sensitivity of the methods used in this study, of those who were diagnosed with psychotic 
disorder in the community and reported it as adults, all were captured in our screening procedures, and 
none of those who screened negative reported a community diagnosis of psychotic disorder.  
Delusions and auditory hallucinations were the most common type of psychotic symptom 
reported.  The repeated, prospective, within-subject assessments showed that most psychotic 
experiences were transient.  These findings are consistent with reports that psychotic experiences in the 
general population are usually transient and that only a small proportion of the 8-10% who experience 
them develop psychotic disorders.10  Unlike studies in community samples,5 we did not find that lower IQ 
or non-European ethnicity were risk factors for psychotic experiences.  The MTA, however, excluded at 
entry children with IQ below 80.  
The analyses reveal that more frequent use of cannabis, but not of alcohol or other drugs of 
abuse, is associated with a greater risk for screening positive and being confirmed positive for psychotic 




cannabis increases the risk for psychosis.27-33 Specifically, it is the sustained, rather than sporadic, use of 
cannabis by adolescents that has been found to be associated with increased risk of subclinical psychotic 
symptoms, and especially paranoia.29,30   The data from this study show that ADHD per se does not 
increase the risk for cannabis-associated psychotic symptoms.  
Consistently with the well-known association between tobacco use and psychosis,34 the analyses 
also found that the subjects who both screened and were confirmed positive had used nicotine more 
frequently than the other subjects.  However, merely screening positive was not linked to nicotine use.   
Although the role of nicotine in psychosis is still a matter of debate,35 the association of nicotine with 
psychosis is generally considered to reflect common risk factors rather than to be a causal effect. 
In conclusion, in this sample of youths with childhood diagnosis of ADHD-combined type, the 
rate of psychotic symptoms through mean age 25 was not greater than that found in a normative 
comparison group, and was consistent with the epidemiologically expected rate of psychosis.   Psychotic 
symptoms were transient phenomena in about three-fourth of the cases.   The results confirm that 
sustained cannabis use is associated with an increased risk of psychotic experiences, thus supporting the 
recommendation that cannabis should not be used during development. These data also confirm that a 
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Table 1 – Study Sample  
 
 MTA (n=509) LNCG (n=276) p  
Age at Year 16 assessment, years, mean (SD) 
 
25.12 (1.07) 24.58 (1.15) <.0001 
 Male, n (%)  402 (80) 222 (79) 0.63 
Caucasian, n (%) 283 (56) 138 (50) 0.13 
IQ, mean (SD) 101.5 (14.7) 108.7 (19.1) <.0001 
Mother’s mental illness history, n (%)a 101 (22) 37 (14) 0.01 
Father’s mental illness history, n (%)b 69 (18) 25 (11) 0.02 
 
aMTA n=454 and LNCG n=261 




Table 2 – Psychotic Symptom Screening Outcome 
 MTA (n=509) LNCG (n=276) pc  
 N % (95% C.I) N % (95% C.I)  
Screened positive at  
any of the assessment points 
26 5.1 (3.1 – 7.0) 11 3.9 (1.6 – 6.2)  0.60 
Psychosis was confirmed by  
further clinical reviewa 
6 1.1 (0.2 – 2.1) 2 0.7 (0 -1.7) 0.72 
Psychosis was confirmed  
or not ruled outb 
10 1.9 (0.7 – 3.1) 5 1.8 (0.2 – 3.3) 1.00  
 
aClinical review was missing for 4 MTA and 3 LNCG subjects. 
bIncluding the cases with confirmed psychosis and those with missing clinician review 







Table 3 –  Psychosis Symptom Screening and Sex, Ethnicity, IQ and Family Psychiatric History   
 Screened positive  
 
Screened negative  
 
pa 
 (n=37) (n=831)  
Male n (%) 26 (70) 674 (81) 0.10 
    
 (n=35) (n=824)  
Caucasian n (%)  15 (57) 450 (45) 0.17 
    
 (n=37) (n=822)  
IQ, Mean (SD)  99.2 (15.7) 103.6 (16.7) 0.11 
    
 (n=29) (n=763)  
Biological Mother Mental Health Problems, yes n (%) 18 (36) 114 (19) 0.03 
 (n=23) (n=669)  
Biological Father Mental Health Problems, yes n (%) 5 (22) 93 (14) 0.28 
 








Table 4 – Psychotic Symptom Screening and Alcohol, Cannabis, Nicotine, and Other Drugs of Abuse in the MTA and LNCG  
 
 













17 (43) 19 (43) 9 (34) 21 (36)     0.93 
Mean (SD), Range 64.4 (147.8)  
0 - 730 
37.3 (56)  
0 - 677 
56.6 (121.6) 
0 - 415 
31.4 (36.1)  
0 - 230 
 
Marijuana, Median (IQR)  14 (179) 3 (122) 46 (147) 1 (40)    0.03
c 
                    Mean (SD) 
                   Range 
108.7 (155.5)  
0 - 437 
84.1 (156.1)  




0 - 489 
46.3 (95.2) 
0 - 489 
 
Nicotine, Median (IQR) 
0.5 (1.4) 0.5 (1.1) 0.5 (1.0) 0.25 (0.8) 
<0.001
d 
                    Mean (SD) 
                   Range 
0.9 (0.9)  
0 - 3 
0.6 (0.6)  
0 - 3 
0.5 (0.5) 
0 - 1.3 
0.4 (0.5) 
0 - 2.1 
 
Other drugs, Median (IQR)  0 (2) 0 (1) 0 (1) 0 (1)   0.79 
                    Mean (SD) 
                   Range 
23.3 (74.1) 
0 – 366 
10.7 (50.4) 
0 – 547 
10.4 (32.2) 
 0 – 107 
3.8 (15.3), 
0 – 156 
 
 a




Statistically significant difference between positive and negative screens 
d






















Alcohol, Median (IQRb) 
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Marijuana, Median (IQR)  
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Title and foot-note for Fig. 1 (next page) 
Figure 1 – Frequency of cannabis use among the positive (n=37) and negative screens (n=748) for 
psychotic experiencesa  
a













Supplemental Tab. 1:  Screening for Hallucinations and Delusions  
 
 
 Yr 6 Yr 8  Yr 10 Yr 12 Yr 14 Yr 16 
Scorea 1 2 3 4 Total 1 2 3 Total 1 2 3 Total 1 2 3 Total 1 2 3 4 Total 1 2 3 4 Total 
Auditory  
Hallucinations 
                           
MTA 276 10 4 0 290 400 19 3 422 396 11 3 410 402 9 3 414 420 13 2 1 436 402 10 3 2 417 
LNCG 185 5 1 0 191 250 6 1 257 246 6 0 252 242 5 0 247 247 2 0 1 250 239 0 1 0 240 
                            
Visual  
Hallucinations 
                           
MTA 283 4 1 2 290 416 6 1 423 397 12 1 410 403 9 2 414 428 3 5 0 436 410 5 2 0 417 
LNCG 186 5 0 0 191 254 2 1 257 249 3 0 252 246 1 0 247 246 4 0 0 250 239 1 0 0 240 
                            
Somatic 
Hallucinationsb 
                           
MTA              406 7 1 414 427 6 3 0 436 407 7 3  417 
LNCG              243 3 1 247 248 2 0 0 250 236 3 1  240 
                            
Delusions                            
MTA 271 15 3 0 289 409 13 0 422 393 14 3 410 399 13 1 413 425 9 2 0 436 402 11 3 1 417 





1 = Symptom not present  
2 = Symptom possibly present but not psychotic (e.g., hearing own voice inside the head, visual images of dead person, somatic sensations form medical 
disorder)  
3 = Symptom probably present and psychotic  
4 = Symptom definitely present 
 





Supplemental Table 2 - Reported Community Diagnoses for the Subjects who Screened positive  
Initially screened 
positive for: 
N Psychosis was excluded by further clinical review   
N      Reported diagnoses 
Psychosis was not excluded by further clinical reviewa   
N       Reported diagnoses                    
Auditory 
hallucinations only 
6 6 none 0 n.a. 
Auditory and visual 
hallucinations  
1 1 major depression and personality disorder 0 n.a. 
Auditory, visual and 
somatic 
hallucinations 




4 2 obsessive-compulsive disorder (1); none (1)  2 schizoaffective (2) 
Auditory and visual 
hallucinations and 
delusions 
1 1 none 0 n.a. 








1 0 n.a. 1 none 
Visual hallucinations 3 2 none (1); anxiety disorder NOS (1) 1 bipolar 
Visual and somatic 
hallucinations 
1 0 n.a. 1 alcohol abuse 
Visual and delusions 1 1 none 0 n.a. 
Somatic 
hallucinations 
2 1 none 1 none 
Delusions only  12 8 none (6); PTSD and cannabis and opiate abuse 
(1); generalized anxiety and mood disorder NOS 
4 none (1); schizophrenia (1); schizoaffective disorder 





Social isolation  1 1 none 0 n.a. 
      
Cumulative (any 
psychotic symptom) 
37 24 none (19); schizophrenia or schizoaffective 
disorder (0); other disorders (5) 
13 none (3); schizophrenia or schizoaffective  
disorder (5);b bipolar (1); other disorders (4) 
 
n.a.: not applicable 
OCD: obsessive compulsive disorder 
NOS: not otherwise specified 
 
aIncluding cases with confirmed or possible psychosis at clinician’s review and cases for whom the clinician’s review was missing 







Supplemental Table 3 – Sensitivity Analysis: Psychotic Symptom Screening Outcome, After Excluding n=27 LNCG with Diagnosable 
ADHD 
 MTA (n=509) LNCG (n=249) pc  
 N % (95% C.I) N % (95% C.I)  
Screened positive at  
any of the assessment points 
26 5.1 (3.1 – 7.0) 10 4.0 (1.5 – 6.4)  0.59 
Psychosis was confirmed by  
further clinical reviewa 
6 1.1 (0.2 – 2.1) 1 0.4 (0.03 -1.1) 0.67 
Psychosis was confirmed  
or not ruled outb 
10 1.9 (0.7 – 3.1) 4 1.6 (0 – 3.1) 1.00  
aClinical review was missing for 4 MTA and 3 LNCG subjects. 
bIncluding the cases with confirmed psychosis and those with missing clinician review 
cFisher’s exact test 
 
  
Supplemental Table 4 – Sensitivity Analysis: Psychotic Symptom Screening and Alcohol, Cannabis, and Other Drug of Abuse in the 
MTA and LNC, After Excluding n=27 LNCG with Diagnosable ADHD 
 
 













17 (43) 19 (43) 14(43) 21 (35)   0.94 
Mean (SD),  
Range 
64.4 (147.8)  
0 - 730 
37.3 (56)  
0 - 677 
61.6 (127.1) 
0 - 415 
30.1 (32.9)  
0 – 229 
 




108.7 (155.5),  
0 - 437 
84.1 (156.1),  
0 - 1095 
98.1 (155.1),  
0 - 489 
43.3 (93.1) 
0 - 489 
 
Other drugs, Median (IQR)  0 (2) 0 (1) 0 (2) 0 (1)   0.61 
 Mean (SD) 
 Range 
23.3 (74.1) 
0 – 366 
10.7 (50.4) 
0 – 547 
11.4 (33.7) 
 0 – 107 
3.1 (12.3), 
0 – 156 
 
 a








Supplemental Table 5 – Sensitivity Analysis: Psychotic Symptom Screening and Alcohol, Cannabis, and Other Drug of Abuse, After 


































































IQR = Interquartile Rage (difference between upper and lower quartiles) 
 
 
 
